(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74812 A1

(51) International Patent Classification[7]: C07D 417/04, A61K 31/428, 31/5415, A61P 31/04

(21) International Application Number: PCT/US01/08623

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/193,631 31 March 2000 (31.03.2000) US

(71) Applicant *(for all designated States except US)*: **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CISKE, Fred, L.** [US/US]; 26431 Riesling Summit, Lawton, MI 49065 (US). **GENIN, Michael, J.** [US/US]; 33303 Walden Way, Paw Paw, MI 49079 (US).

(74) Agent: YANG, Lucy, X.; Intellectual Property Legal Services, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/74812 A1

(54) Title: NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS



(1)

(57) Abstract: The present invention provides a compound of formula (1) wherein M is $-CH_2-$ or $-CH_2CH_2-$, which have potent antibacterial activities.

NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS

FIELD OF THE INVENTION

The present invention relates to novel benzosultam oxazolidinones, specifically relates to N-substituted bicyclic benzosultam oxazolidinones; and their preparations. These compounds have potent antibacterial activities.

BACKGROUND OF THE INVENTION

The oxazolidinone antibacterial agents are a novel synthetic class of antimicrobials with potent activity against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as *Mycobacterium tuberculosis* and *Mycobacterium avium*. The benzosultam oxazolidinones of the present invention may also possess activities against gram-negative organisms such as *Haemophilus influenza* and *Moraxella catarrhalis*.

INFORMATION DISCLOSURE

US Patent No. 5,164,510 discloses 5'-indolinyloxazolidin-2-ones which are useful as antibacterial agents.

US Patent Nos. 5,036,092; 5,036,093; 5,039,690; 5,032,605 and 4,965,268 disclose aminomethyl oxazolidinyl aza cycloalkylbenzene derivatives useful as antibacterial agents.

US Patent Nos. 5,792,765 and 5,684,023 disclose substituted oxazolidinones useful as antibacterial agents.

PCT International Publications WO 98/32438, WO 98/34929, WO 99/36069, WO 9911264, discloses sultam derivatives useful in the treatment of disease states mediated by the chemokine, interleukin-8.

SUMMARY OF THE INVENTION

The present invention provides a compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

R^1 is H, NH_2, NHC_{1-4} alkyl, C_{1-4} alkenyl, OC_{1-4} alkyl, SC_{1-4} alkyl, $(CH_2)_i$-C_{3-6} cycloalkyl, or C_{1-4} alkyl, optionally substituted with 1-3 F, 1-2 Cl or CN;

R^2 is H, C_{1-12} alkyl optionally substituted with phenyl or CN, or C_{2-12} alkyl substituted with OH, SH, NH_2, -OC_{1-6} alkyl, -NHC_{1-6} alkyl, -$NHCOC_{1-6}$ alkyl, -$NHSO_2C_{1-6}$ alkyl, -$S(O)_iC_{1-6}$ alkyl, or one to three halo;

Y is O or S;

M is $-(CH_2)_n-$, wherein n is 1 or 2 and

i is 0, 1, or 2.

In another aspect, the present invention also provides:

a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier,

a method for treating microbial infections in humans or other warm-blooded animals by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof,

the use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating microbial infections in humans or other warm-blooded animals, and

The invention also contains novel intermediates and processes that are useful for preparing compounds of formula I.

DETAILED DESCRIPTION OF THE INVENTION

The following definitions are used, unless otherwise described.

The term alkyl, alkenyl, etc. refer to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.

The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C_{1-7} alkyl refers to alkyl of one to seven carbon atoms, inclusive.

Warm-blooded animals refer to farm animal, companion animal or other type of animal.

The term "halo" refers to fluoro, chloro, bromo, or iodo

The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system.

Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for hour or hours and "rt" for room temperature).

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

A specific value for R^1 is NH_2, $-OCH_3$, or C_{1-4} alkyl.

A specific value for R^1 is methyl, ethyl, or isopropyl.

A specific value for R^1 is methyl.

A specific value for R_1 is ethyl.

A specific value for R^2 is C_{1-6} alkyl.

A specific value for R^2 is C_{1-6} alkyl substituted with CN.

A specific value for R^2 is benzyl.

A specific value for R^2 is C_{2-6} alkyl substituted with OH, SH, NH_2, F, $-OC_{1-6}$ alkyl, $-NHC_{1-6}$ alkyl, $-NHCOC_{1-6}$ alkyl, $-NHSO_2C_{1-6}$ alkyl, $-S(O)_iC_{1-6}$ alkyl, or one to three halo.

A specific value for R^2 is methyl or methyl substituted with CN.

A specific value for R^2 is ethyl substituted with fluoro or methoxy.

A specific value for R^2 is $-CH_2CH_2F$.

A specific value for Y is sulfur.

A specific value for Y is oxygen.

A specific value for n is 1.

These absolute configurations are called (S)-configuration according to the Cahn-Ingold-Prelog nomenclature system. It will be appreciated by those skilled in the art that compounds of the present invention may have additional chiral centers and be isolated in optically active or racemic form. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention. It is well known in the art how to prepare the optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to

determine activity using the standard tests described herein, or using other similar tests which are well known in the art.

Examples of the present invention are:

(1) N-{[(5S)-3-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide, (PNU-252307)

(2) N-({(5S)-3-[1-(2-Fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, (PNU-254380)

(3) N-({(5S)-3-[1-(2-Nitriloethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, (PNU-274919)

(4) N-({(5S)-3-[1-(2-Methoxyethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, and (PNU-276461)

(5) N-({(5S)-3-[1-(2-Fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide. (PNU-254646)

The following describes the preparation of compounds of the present invention. All of the starting materials are prepared by procedures described herein or by procedures that would be well known to one of ordinary skill in organic chemistry.

As shown in CHART I, nitrobenzosultam **1**, (can be obtained according to the methods described in J. Het. Chem. **1986**, *23*, 1645), is first converted to a sodium salt by treatment with a suitable base such as sodium bicarbonate. The nitrogen at the 1-position can then be alkylated by treatment with a variety of alkylating agents including alkyl halides and heating in a suitable solvent such as DMF. These compounds of general structure **2** can be reduced by catalytic hydrogenation in the presence of a suitable catalyst such as palladium on carbon in a suitable solvent such as ethyl acetate, THF, methanol or combinations thereof to afford 5-aminobenzosultams **3**. When **3** are treated with magnesium triflate and N-[(2S)oxiranylmethyl] acetamide, prepared by the method of Schaus and Jacobsen (Tetrahedron Lett. **1996**, *37*, 7937), in a suitable solvent, preferably acetonitrile, the chiral alcohols **4** can be obtained. These compounds can be cyclized to the desired oxazolidinones **5** by reaction with a carbonyl equivalent such as carbonyl diimidazole or preferably N,N'-disuccinimidyl carbonate with an appropriate base such as triethylamine in a mixed solvent system such as acetonitrile/DMF. Additionally, these oxazolidinone amides can be reacted with a sulfurating agent such as Lawesson's Reagent in an appropriate solvent such as THF to obtain the corresponding thioamides **6**.

CHART I



In CHART II, the compounds wherein n = 2 can be prepared from the known intermediate 7 (Sianesi, E. et al. *Chem. Ber.* **1971**, *104*, 1880). Nitration of structure 7 provides structure 8. The remaining synthetic steps which lead to structure 9 are similar to the procedures outlined in CHART I.

CHART II



It will be apparent to those skilled in the art that the described synthetic procedures are merely representative in nature and that alternative synthetic processes are known to one of ordinary skill in organic chemistry.

The pharmaceutical compositions of this invention may be prepared by combining the compounds of formula I of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compounds of formula I according to this invention.

The quantity of active component, that is the compound of formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the

magnesium trifluoromethanesulfonate (0.42g, 1.3mmol) in dry CH_3CN (10mL) at room temperature. After 20hrs solvent is evaporated and the residue purified by chromatography (4%MeOH/CH_2Cl_2) to give a foamy solid (0.23g, 79%). HRMS (FAB) calcd for $C_{13}H_{19}N_3O_4S$ +H_1 314.1174, found 314.1174.

Step: 3 Preparation of N-{[(5S)-3-(1-methyl-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide PNU-252307

The previous product (0.20g, 0.63mmol) is dissolved in CH_3CN (5mL) and DMF (2.5mL). *N,N'*-Disuccinimidyl carbonate (0.23g, 0.90mmol) is added followed by triethylamine (0.26mL, 1.9mmol) and the mixture stirred at room temperature for 20hrs. The mixture is poured into CH_2Cl_2 (30mL) and washed with H_2O (3x20mL). The organics are dried (Na_2SO_4), filtered and solvent evaporated. The residue is chromatographed (3%MeOH/CH_2Cl_2) to obtain a white solid (0.142g, 66%). Mp 84-6 °C. HRMS (FAB) calcd for $C_{14}H_{17}N_3O_5S$ +H_1 340.0967, found 340.0965.

Example 2 Preparation of N-({(5S)-3-[1-(2-fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-254380



Step 1: Preparation of 1-(2-fluoroethyl)-5-nitro-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione

$NaHCO_3$ (0.93g, 11.0mmol) is dissolved in H_2O (15mL) and 5-Nitro-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione (1) (1.90g, 8.9mmol) is added with stirring. The mixture is heated to 80°C for 0.5 hrs and a yellow solid formed. The mixture is cooled to 0°C and filtered. The solid is washed with cold H_2O (15mL) then with cold EtOH (25mL). The yellow solid thus obtained is dried under high vacuum then dissolved in dry DMF (15mL). 1-Bromo-2-fluoroethane (1.52 mL, 20.0mmol) is added and the solution heated to 100°C for 4 hrs. The solution is cooled to room temperature then poured into ice water (50mL). The solid is collected by filtration and gave crystals (1.55g, 67%) after recrystallization

from EtOH. Mp 142-4 °C. HRMS (FAB) calcd for $C_9H_9FN_2O_4S$ +NA_1 283.0165, found 283.0166.

Step 2: Preparation of 5-amino-1-(2-fluoroethyl)-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione

The product of Step 1 (1.25g, 4.8mmol) is dissolved into EtOAc (30mL) in a Parr bottle and 10% Pd/C (100mg) added under nitrogen. The mixture is hydrogenated on a Parr apparatus for 4 hrs at 40psi. Filtration and evaporation of solvent gave a solid (1.1g, 99%). Mp 119-21 °C. HRMS (FAB) calcd for $C_9H_{11}FN_2O_2S$ +H_1 231.0603, found 231.0610.

Step 3: N-({(5S)-3-[1-(2-fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-254380

The previous 5-amino product (0.95g, 4.1mmol) is added to a mixture of N-[(2S)oxiranylmethyl] acetamide (0.81g, 7.0mmol) and magnesium trifluoromethanesulfonate (2.0g, 6.2 mmol) in dry CH_3CN (45mL) at room temperature. After 20hrs solvent is evaporated and the residue chromatographed (4% MeOH/CH_2Cl_2). The intermediate product is dissolved in CH_3CN (25mL) and DMF (12mL). *N,N'*-Disuccinimidyl carbonate (2.25g, 9.0mmol) is added followed by triethylamine (2.6mL, 18.8mmol) and the mixture stirred at room temperature for 20hrs. The mixture is poured into CH_2Cl_2 (30mL) and washed with H_2O (3x20mL). The organics are dried (Na_2SO_4), filtered and solvent evaporated. The residue is chromatographed (3%MeOH/CH_2Cl_2) to obtain a white solid (0.58g, 38%). Mp 84-7 °C (dec). HRMS (FAB) calcd for $C_{15}H_{18}FN_3O_5S$ +H_1 372.1029, found 372.1021.

Example 3 Preparation of N-({(5S)-3-[1-(2-nitriloethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-274919



Step 1: Preparation of 2-(5-nitro-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-1-yl)acetonitrile

$NaHCO_3$ (1.48g, 17.6mmol) is dissolved in H_2O (20mL) and 5-Nitro-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione (1) (3.17g, 14.8mmol) is added with stirring. The mixture is

heated to 80°C for 0.5 hrs and a yellow solid formed. The mixture is cooled to 0°C and filtered. The solid is washed with cold H_2O (25mL) then with cold EtOH (45mL). The yellow solid thus obtained (intermediate sodium salt) is dried under high vacuum. A portion of this material (1.0g, 4.2mmol) is dissolved in dry DMF (7.0mL). Bromoacetonitrile (0.34mL, 5.0mmol) is added and the solution heated to 100°C for 2 hrs. The solution is cooled to room temperature then poured into ice water (50mL). The solid is collected by filtration and gave an off-white solid (0.73g, 69%) after recrystallization from EtOH. Mp 200-2 °C. HRMS (FAB) calcd for $C_9H_7N_3O_4S$ $+H_1$ 254.0235, found 254.0235.

Step 2: N-({(5S)-3-[1-(2-nitriloethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-274919

The product of Step 1 (0.73g, 2.9mmol) is dissolved into EtOAc (30mL) in a Parr bottle and 10% Pd/C (100mg) added under nitrogen. The mixture is hydrogenated on a Parr apparatus for 2 hrs at 40psi. Filtration and evaporation of solvent gave a yellow solid which is added to a mixture of N-[(2S)oxiranylmethyl]acetamide (0.97g, 8.0mmol) and magnesium trifluoromethanesulfonate (1.3g, 4.0 mmol) in dry CH_3CN (30mL) at room temperature. After 20hrs solvent is evaporated and the residue chromatographed (4% $MeOH/CH_2Cl_2$). The intermediate product is dissolved in CH_3CN (20mL) and DMF (10mL). *N,N'*-Disuccinimidyl carbonate (1.0g, 4.1mmol) is added followed by triethylamine (1.2mL, 8.7mmol) and the mixture stirred at room temperature for 20hrs. The mixture is poured into CH_2Cl_2 (30mL) and washed with H_2O (3x20mL). The organics are dried (Na_2SO_4), filtered and solvent evaporated. The residue is chromatographed (3%$MeOH/CH_2Cl_2$) to obtain a pale yellow solid (0.12g, 11%). Mp 124-6 °C (dec). HRMS (FAB) calcd for $C_{15}H_{16}N_4O_5S$ $+H_1$ 365.0919, found 365.0915.

Example 4 Preparation of N-({(5S)-3-[1-(2-methoxyethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-276461



Step 1: 1-(2-methoxyethyl)-5-nitro-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione

$NaHCO_3$ (1.48g, 17.6mmol) is dissolved in H_2O (20mL) and 5-Nitro-1,3-dihydro-2H-2,1-benzisothiazole-2,2-dione (1) (3.17g, 14.8mmol) is added with stirring. The mixture is heated to 80°C for 0.5 hrs and a yellow solid formed. The mixture is cooled to 0°C and filtered. The solid is washed with cold H_2O (25mL) then with cold EtOH (45mL). The yellow solid thus obtained (intermediate sodium salt) is dried under high vacuum. A portion of this material (1.0g, 4.2mmol) is dissolved in dry DMF (7.0mL). 2-Bromoethyl methyl ether (1.41mL, 15.0mmol) and potassium iodide (10mg) are added and the solution heated to 130°C for 5 days. The solution is cooled to room temperature then poured into ice water (50mL). The solid is collected by filtration and gave a solid (0.77g, 67%) after chromatography (50% EtOAc/ Heptane). Mp 130-2 °C. HRMS (FAB) calcd for $C_{10}H_{12}N_2O_5S + H_1$ 273.0545, found 273.0548.

Step 2: N-({(5S)-3-[1-(2-methoxyethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide PNU-276461

The product of Step 1 (0.70g, 2.6mmol) is dissolved into EtOAc (30mL) in a Parr bottle and 10% Pd/C (100mg) added under nitrogen. The mixture is hydrogenated on a Parr apparatus for 2 hrs at 40psi. Filtration and evaporation of solvent gave a residue which is added to a mixture of N-[(2S)oxiranylmethyl]acetamide (0.115g, 1.0mmol) and magnesium trifluoromethanesulfonate (0.32g, 1.0 mmol) in dry CH_3CN (10mL) at room temperature. After 20hrs solvent is evaporated and the residue is dissolved in CH_3CN (10mL) and DMF (5mL). *N,N'*-Disuccinimidyl carbonate (0.30g, 1.2mmol) is added followed by triethylamine (0.34mL, 2.4mmol) and the mixture stirred at room temperature for 20hrs. The mixture is poured into CH_2Cl_2 (30mL) and washed with H_2O (3x20mL). The organics are dried (Na_2SO_4), filtered and solvent evaporated. The residue is chromatographed (3%MeOH/CH_2Cl_2) to obtain a pale yellow foamy solid (0.114g, 38%). HRMS (EI) calcd for $C_{16}H_{21}N_3O_6S$ 383.1151, found 383.1149.

Example 5 Preparation of N-({(5S)-3-[1-(2-fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide PNU-254646



The product from example 2 (0.195g, 0.52mmol) and Lawesson's Reagent (0.21g, 0.52mmol) are stirred in dry THF (20mL) and heated to reflux for 20 hrs. The mixture is cooled to room temperature and solvent evaporated. The residue is chromatographed (4%MeOH/CH_2Cl_2) to give a solid (0.178g, 88%). Mp 90-3 °C (dec). HRMS (FAB) calcd for $C_{15}H_{18}FN_3O_4S_2$ +H_1 388.0801, found 388.0805.

CLAIMS

1. A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

R^1 is

a) H,

b) NH_2,

c) NHC_{1-6} alkyl,

d) C_{1-6} alkenyl,

e) OC_{1-6} alkyl, SC_{1-6} alkyl,

f) $(CH_2)_i$-C_{3-6} cycloalkyl, or

g) C_{1-6} alkyl, optionally substituted with one to three halo;

R^2 is

a) H,

b) C_{1-12} alkyl, optionally substituted with phenyl or CN, or

c) C_{2-12} alkyl substituted with OH, SH, NH_2, -OC_{1-6} alkyl, -NHC_{1-6} alkyl, -$NHCOC_{1-6}$ alkyl, -$NHSO_2C_{1-6}$ alkyl, -$S(O)_iC_{1-6}$ alkyl, or one to three halo;

Y is O or S;

M is $-(CH_2)_n-$, wherein n is 1 or 2; and

i is 0, 1, or 2.

2. A compound of claim I wherein R^1 is NH_2, -OCH_3, or C_{1-4} alkyl.

3. A compound of claim I wherein R^1 is methyl

4. A compound of claim I wherein R^1 is ethyl.

5. A compound of claim I wherein R^2 is C_{1-6} alkyl, optionally substituted with phenyl or CN.

6. A compound of claim I wherein R^2 is C_{2-6} alkyl substituted with OH, SH, NH_2, F, $-OC_{1-6}$ alkyl, $-NHC_{1-6}$ alkyl, $-NHCOC_{1-6}$ alkyl, $-NHSO_2C_{1-6}$ alkyl, or $-S(O)_iC_{1-6}$ alkyl.

7. A compound of claim I wherein R^2 is C_{1-4} alkyl optionally substituted with CN, or C_{2-4} alkyl substituted with fluoro or OC_{1-4} alkyl.

8. A compound of claim I wherein R^1 is C_{1-4} alkyl; R^2 is C_{1-4} alkyl optionally substituted with CN, or C_{2-4} alkyl substituted with fluoro or OC_{1-4} alkyl; Y is sulfur or oxygen; and n is 1.

9. A compound of claim 8 wherein Y is sulfur.

10. A compound of claim 8 wherein R^1 is CH_3 or CH_3CN; R^2 is CH_2CH_2F or $CH_2CH_2OCH_3$; Y is sulfur or oxygen, n is 1.

11. A compound of claim 10 wherein Y is sulfur.

12. A compound of claim 1 which is

(a) N-{[(5S)-3-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide,

(b) N-({(5S)-3-[1-(2-Fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide,

(c) N-({(5S)-3-[1-(2-Nitriloethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide,

(d) N-({(5S)-3-[1-(2-Methoxyethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, or

(e) N-({(5S)-3-[1-(2-Fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

13. A compound of claim 1 which is N-({(5S)-3-[1-(2-Fluoroethyl)-2,2-dioxo-2,3-dihydro-1H-2,1-benzisothiazol-5-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

14. A use of compounds of claims 1 through 13 for manufacturing of medicinals for treating microbial infections.

15. The use of claim 14 wherein said medicinal is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

16. The use of claim 14 wherein said medicinal is administered in an amount of from about 0.1 to about 500 mg/kg of body weight/day.

17. The use of claim 14 wherein said medicinal is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

18. A use for treating microbial infections of claim 14 wherein the infection is skin infection.

19. A use for treating microbial infections of claim 14 wherein the infection is eye infection.

20. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

Ir tional Application No
PCT/US 01/08623

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D417/04 A61K31/428 A61K31/5415 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 164 510 A (BRICKNER S J) 17 November 1992 (1992-11-17) cited in the application the whole document, particularly example 148	1-20
Y	EP 0 738 726 A (BAYER AG) 23 October 1996 (1996-10-23) the whole document, particularly example 102	1-20
Y	WO 99 37641 A (BAYER AKTIENGESELLSCHAFT) 29 July 1999 (1999-07-29) the whole document, particularly example 107	1-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 July 2001	19/07/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Allard, M

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 01/08623

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5164510 A	17-11-1992	US 5182403 A	26-01-1993
		US 5225565 A	06-07-1993
		AT 112773 T	15-10-1994
		AT 201870 T	15-06-2001
		AU 617871 B	05-12-1991
		AU 4195789 A	02-04-1990
		CA 1335103 A	04-04-1995
		DE 68918792 D	17-11-1994
		DK 45591 A	13-03-1991
		EP 0359418 A	21-03-1990
		EP 0434714 A	03-07-1991
		EP 0609905 A	10-08-1994
		HK 1002234 A	07-08-1998
		JP 11080139 A	26-03-1999
		JP 2865211 B	08-03-1999
		JP 4500665 T	06-02-1992
		KR 138262 B	15-05-1998
		WO 9002744 A	22-03-1990
EP 738726 A	23-10-1996	DE 19544106 A	24-10-1996
		AU 705071 B	13-05-1999
		AU 5073596 A	31-10-1996
		BG 100525 A	31-03-1997
		BR 9602016 A	07-04-1998
		CA 2174473 A	22-10-1996
		CN 1138582 A	25-12-1996
		CZ 9601142 A	16-07-1997
		HR 960159 A	31-08-1997
		HU 9601001 A	28-04-1998
		JP 8301869 A	19-11-1996
		NO 961559 A	22-10-1996
		NZ 286400 A	27-04-1998
		SG 52774 A	28-09-1998
		SK 50096 A	07-05-1997
		TR 960963 A	21-11-1996
		US 6069160 A	30-05-2000
		ZA 9603138 A	04-11-1996
WO 9937641 A	29-07-1999	DE 19802239 A	29-07-1999
		AU 2616199 A	09-08-1999
		EP 1049692 A	08-11-2000